OH2 Injection in Combination With HX008 for Melanoma.

Binhui Biopharmaceutical

Status and phase: Enrolling; Phase 2; Phase 1

Conditions: Melanoma

Treatments: Biological: HX008 injection; Biological: OH2 injection

Study type: Interventional

Funder types: Industry

Identifiers

NCT04616443

OH2-I-ST-03

Details and patient eligibility

About

This phase Ib study evaluates the safety and efficacy of OH2 in combination with HX008, an anti-PD-1 antibody, in patients with Melanoma.

OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF) may induce a more potent antitumor immune response.

Full description

The trial is a phase Ib study evaluating the safety and efficacy of OH2 injection combined with HX008 injection in patients with Melanoma.

In the Phase Ib dose escalation trial, two doses (1x10e6, 1x10e7 CCID50/mL) of OH2 will be combined with HX008(at a fixed dose of 200mg) will be tested.

In the Phase Ib dose expansion trial, OH2(1x10e7 CCID50/mL) will be injected individually in the first week, followed by every two weeks while HX008(200 mg) will be injected every three weeks after the first injection which will be in the second week.

Blood samples will be collected and radiological imaging will be performed to evaluate safety and efficacy during the trial. Besides, patients will be subjected to cutaneous swabs, and blood/urine/feces sampling to determine virus shedding. Participating patients will be evaluated for objective response rate, progression free survival and overall survival.

Enrollment: 60 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. The non-operative stage III or stage IV malignant tumor patients with clear diagnosis by pathology.
2. Patients who have failed in conventional treatment (including PD-1 monotherapy) (disease progression or intolerance) or who have failed in previously assisted PD-1 monotherapy (last assisted PD-1 treatment relapse or metastasis within 6 months).
3. Patients with Eastern Collaborative Oncology Group (ECOG) Performance Status ≤ 1, expected survival time more than 3 months.
4. Prior anti-tumor treatment (including endocrine, chemical/ radiotherapy,targeted therapy) was over 4 weeks (more than 6 weeks of discontinuation using nitroso-and mitomycin-based chemotherapy) and was recovered to grade 1 from the side effects of prior treatment.
5. There is at least one measurable lesion that is suitable for intratumoral injection. The measured tumor focus is defined as the longest diameter ≥ 5 mm.
6. Asymptomatic central nervous system metastasis, or treated asymptomatic brain metastasis patients, must be examined by a computerized fault scan (CT) or MRI for disease-free progression, stable for at least 3 months, and at least 4 weeks without steroid medication.
7. (a) WBC≥3.0×109／L，ANC≥2.0×109／L ，PLT≥100×109／L，Hb≥90 g/L； (b) BUN and Scr. were in the upper limit of 1.5 times of the normal value; (c) TBIL≤ 1.5 times the upper limit of the normal value. (d) ALT and AST ≤ 2.5 times the upper limit of normal value; The value of patients with liver metastasis did not exceed 5 times the upper limit of normal value. (e) Coagulation function is normal (PT and APPT are within 1.5 times of the upper limit of normal value).
8. Female subjects and their spouses received effective contraceptives during and within 3 months of treatment.
9. Subjects with herpes in the reproductive organs needed three months after the end of herpes.
10. The informed consent was voluntarily signed and the expected compliance was good.

Exclusion criteria

1. Severe medical diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, severe infection, active digestive tract ulcer, abnormal immune function (including, but not limited to, rheumatoid arthritis, lupus erythematosus, Sjogren's syndrome, etc.).

2. Significant surgery is expected to be performed during the 28-day screening period during the study period.

3. Patients had active infections or unexplained fevers (over 38.5℃)during screening and before the first drug use.

4. Past or present immunodeficiency diseases.

5. The lesions do not meet the requirements of injection capacity(1ml) in the tumor body.

6. Pregnant or lactating women.

7. Other experimental therapies or antiviral therapy are used or are being used within 4 weeks of treatment.

8. Allergy to herpes virus and drug ingredients.

9. History of primary grape-film melanoma or other malignant tumors in the 5 years prior to treatment.

10. History of tuberculosis, or have tuberculosis at the time of screening.

11. Suffering from sudden lung disease, intersex lung disease, intersex pneumonia, pulmonary fibrosis, acute lung disease, radioactive pneumonia etc.

12. Patients with active autoimmune diseases or with a history of autoimmune diseases that may relapse, except for:

    1. Type I diabetes with stable condition after taking a fixed dose of insulin;
    2. Hypothyroidism;
    3. Controlled celiac disease;
    4. Skin diseases that do not require systemic treatment;
    5. Any other disease that does not re-occur without external triggers.

13. Concurrent medical condition requiring the use of cortisol (>10mg/day prednisone or equivalent dose) or other systematic immunosuppressive medications within 14 days before the study treatment, except for inhalation or topical corticosteroids no more than 10 mg/day prednisone or equivalent.

14. The researchers believe that there is any reason why the patient is not suitable to participate in this trial.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

60 participants in 1 patient group

Dose escalation

Experimental group

Description:

The HX008 injection is combined with OH2 injections at 10ˆ6 and 10ˆ7 CCID50/mL at a fixed dose of 200 mg, respectively. OH2 will be injected individually in the first week, followed by every two weeks while HX008 will be injected every three weeks after the first injection which will be in the second week.

Treatment:

Biological: OH2 injection

Biological: HX008 injection